Promoted Content Promoted Content

X

Find Drugs for Rare Diseases and Disorders in Phase I Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRGN-2012

            Therapeutic Area: Rare Diseases and Disorders Product Name: PRGN-2012

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2021

            Details:

            PRGN-2012 is under development through a Cooperative Research and Development Agreement (CRADA) with the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RP-L401

            Therapeutic Area: Rare Diseases and Disorders Product Name: RP-L401

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: California Institute for Regenerative Medicine

            Deal Size: $3.7 million Upfront Cash: Undisclosed

            Deal Type: Funding November 13, 2020

            Details:

            Clinical Grant of $3.7 M to Fund US Phase 1 Study of RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis. This will be Rocket’s second CIRM grant after receiving one in 2019 for the development of the company’s gene therapy for Leukocyte Adhesion Deficiency-I.